An Open-Label, Controlled, Randomized Phase 3 Trial Evaluating 12-Month Kidney Function in Highly Sensitized (cPRA =99.9%) Kidney Transplant Patients with Positive Crossmatch Against a Deceased Donor, Using Imlifidase with Standard of Care

Investigator: Ahmed Gaber, MD

Study Coordinator: Beatriz Efron

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT04935177

Phone: 713.363.8890

Protocol Number: PRO00031828

Description

An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA =99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care. Subsequently the patient will be randomized in a 1:1 ratio to the imlifidase or the control arm. If the patient is randomized to the imlifidase arm, the organ will be accepted and shipped, and the patient will proceed to imlifidase treatment (generally within 24 h prior to transplantation) followed by transplantation. If the patient is randomized to the control arm, transplantation made possible by the local desensitization regimen will occur. If the institution-specific desensitization protocol is deemed not to be successful, the organ offer will be turned down, and the patient will remain active on the waiting list and remain in the trial, while the kidney will be allocated to another recipient through the kidney allocation system (KAS). All transplanted patients will receive induction therapy and maintenance immunosuppression. All patients will be followed for 12 months. Estimated glomerular filtration rate (eGFR) will be assessed 12 months after randomization as the primary endpoint reasonably likely to predict a clinical benefit in patient survival. All patients with donor specific antibodies (DSA) are at risk of developing antibody-mediated rejection (AMR). Imlifidase removes DSA quickly and efficiently at the time of transplantation but, as with other desensitization methods, the antibodies are expected to re-occur after transplantation. In the imlifidase treatment arm, and for desensitized control arm patients, protocol kidney biopsies will be performed at the time of transplantation and at 1 year after transplantation.
More to Explore